| abstract |
The present invention relates to 17,20 (E) -dehydrovitamin D analogs, and in particular 17 (E) -1α, 25-dihydroxy-17 (20) -dehydro-2-methylene-19-nor-vitamin D 3 , and Its pharmaceutical use is disclosed. This compound shows significant activity in suppressing the proliferation of undifferentiated cells and inducing their differentiation into monocytes, and therefore as an anti-cancer agent and also in skin diseases such as psoriasis, as well as skin conditions such as wrinkles, skin Demonstrate use for the treatment of sagging, dry skin and insufficient sebum secretion. This compound also has little, if any, plasma calcium raising activity and is therefore used to treat human autoimmune and inflammatory diseases, as well as renal osteodystrophy and obesity. Good. [Selection] Figure 1 |